{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T21:16:33Z","timestamp":1772572593798,"version":"3.50.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bristol-Myers Squibb K.K"},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co., Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Many patients with classical Hodgkin lymphoma show increased programmed death-1 ligand expression in Reed\u2013Sternberg cells. We report the final results of a phase II study of nivolumab, an anti-programmed death-1 monoclonal antibody, in Japanese patients with relapsed or refractory classical Hodgkin lymphoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Japanese patients with previously treated classical Hodgkin lymphoma (aged \u2265 20\u00a0years) were administered nivolumab (3\u00a0mg\/kg on Day 1 of 14-day\u00a0cycles) until progressive disease, an unacceptable adverse event, or another clinically relevant reason. Treatment could continue beyond progressive disease at the investigator\u2019s discretion in selected patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventeen patients (median age: 63.0\u00a0years) were enrolled. The median follow-up was 38.8\u00a0months. One patient with non-Hodgkin lymphoma was excluded from efficacy analyses. The centrally assessed overall response rate in 16 classical Hodgkin lymphoma patients was 87.5% (95% confidence interval = 61.7\u201398.4%) and the disease control rate was 93.8% (95% confidence interval = 69.8\u201399.8%). The median (95% confidence interval) duration of response and progression-free survival were 8.5 (2.4\u201312.6) and 11.7 (1.8\u201342.3) months, respectively. The 3-year overall survival rate was 80.4% (95% confidence interval = 50.6\u201393.2%). Nivolumab was continued beyond progressive disease in seven patients; six were alive at the data cut-off. Adverse drug reactions occurred in all 17 patients with grades 3\u20134 adverse drug reactions in eight patients and no grade 5 adverse drug reactions. Pulmonary toxicities occurred in five patients; four of these occurred \u226517\u00a0months after starting nivolumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Nivolumab is effective and tolerable in Japanese relapsed or refractory classical Hodgkin lymphoma patients. Continued monitoring may be necessary to detect late-onset pulmonary toxicities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical trial registration<\/jats:title>\n                  <jats:p>JapicCTI-142755 (Japan Pharmaceutical Information Center).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyaa117","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T11:16:05Z","timestamp":1592478965000},"page":"1265-1273","source":"Crossref","is-referenced-by-count":18,"title":["Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma"],"prefix":"10.1093","volume":"50","author":[{"given":"Dai","family":"Maruyama","sequence":"first","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Terui","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8588-8955","authenticated-orcid":false,"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Hematology, NHO Kyushu Cancer Center, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Tokai University, Isehara, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Hattori","sequence":"additional","affiliation":[{"name":"Medical Affairs, Ono Pharmaceutical Co., Ltd., Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,8,8]]},"reference":[{"key":"2020102205350720000_ref1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2020102205350720000_ref2","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.mayocp.2015.07.005","article-title":"Hodgkin lymphoma: diagnosis and treatment","volume":"90","author":"Ansell","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"2020102205350720000_ref3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12185-016-2007-1","article-title":"Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma","volume":"104","author":"Makita","year":"2016","journal-title":"Int J Hematol"},{"key":"2020102205350720000_ref4","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-019-0788-0","article-title":"Controversies in the approach to initial therapy of Hodgkin lymphoma","volume":"21","author":"Allen","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"2020102205350720000_ref5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/PPO.0000000000000168","article-title":"Targeting CD30 using brentuximab vedotin in the treatment of Hodgkin lymphoma","volume":"22","author":"Alperovich","year":"2016","journal-title":"Cancer J"},{"key":"2020102205350720000_ref6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"2020102205350720000_ref7","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"2020102205350720000_ref8","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2020102205350720000_ref9","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-16-1387","article-title":"Nivolumab in the treatment of Hodgkin lymphoma","volume":"23","author":"Ansell","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2020102205350720000_ref10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/PPO.0000000000000331","article-title":"Immunotherapy of Hodgkin lymphoma: mobilizing the patient\u2019s immune response","volume":"24","author":"Ansell","year":"2018","journal-title":"Cancer J"},{"key":"2020102205350720000_ref11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"2020102205350720000_ref12","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/bmt.2015.346","article-title":"Major clinical response to nivolumab in relapsed\/refractory Hodgkin lymphoma after allogeneic stem cell transplantation","volume":"51","author":"Yared","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2020102205350720000_ref13","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"2020102205350720000_ref14","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"2020102205350720000_ref15","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"2020102205350720000_ref16","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: two-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"2020102205350720000_ref17","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/cas.13230","article-title":"Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma","volume":"108","author":"Maruyama","year":"2017","journal-title":"Cancer Sci"},{"key":"2020102205350720000_ref18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2020102205350720000_ref19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12185-016-2101-4","article-title":"Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma","volume":"105","author":"Munakata","year":"2017","journal-title":"Int J Hematol"},{"key":"2020102205350720000_ref20","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1001\/jamaoncol.2017.1588","article-title":"Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials","volume":"3","author":"Long","year":"2017","journal-title":"JAMA Oncol"},{"key":"2020102205350720000_ref21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1470-2045(17)30846-X","article-title":"Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis","volume":"19","author":"Beaver","year":"2018","journal-title":"Lancet Oncol"},{"key":"2020102205350720000_ref22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J Clin Med"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/11\/1265\/33981288\/hyaa117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/11\/1265\/33981288\/hyaa117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T09:35:25Z","timestamp":1603359325000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/50\/11\/1265\/5885451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,8]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,8,8]]},"published-print":{"date-parts":[[2020,10,22]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaa117","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,8,8]]}}}